In LPS-stimulated RAW264.7 mouse macrophages, 30 μM bergenin reduced IL-6 and TNF-α mRNA and secreted protein after 24 h. In uric-acid-exposed human HK-2 cells, 50–100 μM bergenin altered ABCG2 and SLC2A9 expression; the ABCG2 response at 50 μM depended on PPARγ in knockdown and antagonist experiments. These are model-specific cellular findings, not direct cytokine or urate-transporter inhibition constants. [1,2]
Competitive binding to the PPARγ ligand-binding domain
Biochemical assay · GST-fused human PPARγ ligand-binding domain in a TR-FRET competitive binding assay [1]
Bergenin competed in a PPARγ ligand-binding assay, with a reported Ki of 2.58 μM. Rosiglitazone was the positive comparator (Ki 0.02 μM). This binding result does not establish receptor selectivity.
Literature-Reported Treatment Conditions
- Exposure duration
- 3 h
- Method
- Cell-free competitive ligand-binding assay at room temperature.
- Reported limits
- Exact tested concentration series, compound vehicle and Ki fitting procedure were not specified in the relevant methods. No dosing recommendation is inferred.
Methods and source locations
Compound reported in the paper: Bergenin
Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.
Chemicals and Reagents; Competition Binding Assay; PPARγ activation Results and Figure 7B
Binding to the human PPARγ ligand-binding domain: LanthaScreen TR-FRET competitive binding assay; 520/495 nm emission ratio — Competition Binding Assay; Activation of Bergenin on PPARγ; Figure 7B
Macrophage cytokine suppression and PPARγ reporter activity
Cell-based study · RAW264.7 mouse macrophages; cytokine, viability and PPARγ reporter endpoints [1]
At 30 μM, bergenin reduced LPS-stimulated IL-6 and TNF-α mRNA and secreted protein in RAW264.7 cells. PPARγ reporter activity increased in RAW264.7 cells at 10 and 30 μM. Bergenin alone did not reduce MTT viability over 1–30 μM under the tested conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3, 10, 30 μM for cytokines/reporter; 1, 3, 10, 30 μM for viability
- Exposure duration
- 24 h
- Method
- Cell treatment; cytokine and reporter arms included LPS stimulation.
- Vehicle
- Not specified for bergenin treatment.
- Co-treatment
- LPS 1 μg/mL in cytokine and reporter experiments; rosiglitazone 30 μM was a separate reporter comparator.
- Reported limits
- No cytokine IC50 or numerical reporter EC50 was reported in these locations; plotted magnitudes were not digitized.
Methods and source locations
Compound reported in the paper: Bergenin
Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.
Chemicals and Reagents; Cell Culture and Viability Assay; Luciferase Assay; Figure 3A–C and Figure 7D
IL-6 and TNF-α mRNA and secreted protein: Q-PCR and ELISA; mean ± SEM, three independent experiments — Figure 3B–C and corresponding cytokine Results
Macrophage viability with bergenin alone: MTT; 20 h exposure followed by 4 h with MTT (24 h total in Figure 3 caption) — Cell Culture and Viability Assay; Figure 3A
PPRE-driven luciferase activity in RAW264.7 cells: Luciferase reporter assay; mean ± SEM, three independent experiments — Luciferase Assay; Figure 7D
Urate-transporter expression in human HK-2 cells
Cell-based study · Human renal proximal tubular epithelial HK-2 cells exposed to soluble uric acid [2]
Bergenin at 50 and 100 μM countered uric-acid-associated ABCG2 downregulation and SLC2A9 upregulation. At 50 μM, the ABCG2 response was lost after PPARγ knockdown or antagonism; PPARγ knockdown did not alter the SLC2A9 response. These are expression and signaling measurements, not a direct transport-inhibition assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30, 50, 100 μM in transporter experiments; 50 μM in PPARγ perturbation arms
- Exposure duration
- 2 h pretreatment followed by 10 h with uric acid; viability assessed after 12 h
- Method
- HK-2 cell treatment.
- Vehicle
- Bergenin-specific vehicle not identified; methods state inhibitors were dissolved in DMSO or water.
- Co-treatment
- Uric acid 8 mg/dL; PPARγ-siRNA or scrambled-siRNA arms; separate GW9662 10 μM and rosiglitazone 30 μM comparisons.
- Reported limits
- No direct urate-flux measurement in the adopted HK-2 experiment. Figure 5 caption provides the 2 h + 10 h timing; generic methods refer to 12 h exposure. The exact vehicle fraction is unavailable.
Methods and source locations
Compound reported in the paper: Bergenin
Evidence concerns the reported bergenin research material; it is not a test of Adooq material or a recommended treatment regimen.
Reagents and Antibodies; Cell Culture; CCK-8; Figure 5A–G and associated HK-2 Results
ABCG2 and SLC2A9 expression: RT-qPCR and western blot; mean ± SEM, n = 3 — Results: Bergenin in vitro Treatment Regulates ... HK-2; Figure 5B–C
PPARγ dependence of ABCG2 response: PPARγ siRNA versus scrambled siRNA; western blot/RT-qPCR; GW9662 comparison — Results: Bergenin Promotes ABCG2 Expression by Activating PPARγ in HK-2 Cells; Figure 5E–G
HK-2 viability: CCK-8 assay — Figure 5A and caption